VITT Pathophysiology: An Update

Area of Science:

• Immunology
• Hematology
• Vaccinology

Background:

• Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare, severe thrombotic disorder associated with adenoviral vector COVID-19 vaccines.
• VITT pathogenesis involves anti-platelet factor 4 (PF4) antibodies causing platelet activation.
• Potential mechanisms include Adv-vector DNA splicing and secretion of SARS-CoV-2 spike variants.

Purpose of the Study:

• To review current knowledge on VITT pathogenesis.
• To highlight recent findings on anti-PF4 antibodies and genetic predisposition.
• To discuss novel VITT-like disorders and intracellular pathways.

Main Methods:

• Literature review of VITT and related disorders.
• Analysis of recent research on anti-PF4 antibody mechanisms.
• Exploration of genetic and metabolic factors in VITT.

Main Results:

• VITT involves specific anti-PF4 antibodies leading to thrombosis and thrombocytopenia.
• VITT-like disorders are identified beyond AdV-vaccine administration, linked to other vaccines and conditions.
• Emerging research points to genetic predisposition and altered lipid metabolism.

Conclusions:

• Understanding VITT pathogenesis is crucial for managing rare vaccine-associated thrombotic events.
• VITT-like disorders expand the spectrum of anti-PF4 associated conditions.
• Further research is needed on genetic factors, intracellular pathways, and lipid metabolism in VITT.